Stimulus-responsive targeted nanomicelles for effective cancer therapy

Nanomedicine

Volumn 4, Issue 6, 2009, Pages 657-667

  Muthu, Madaswamy S ^a   Rajesh, Chellappa V ^b   Mishra, Amit ^b   Singh, Sanjay ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Cancer; Nanomicelles; Stimulus functions; Targeted drug delivery; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COPOLYMER; DOXORUBICIN; FOLIC ACID; NANOMICELLE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL MEMBRANE PERMEABILITY; DETOXIFICATION; DNA REPAIR; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION; HAND FOOT SYNDROME; HUMAN; LIPID COMPOSITION; LUNG TOXICITY; MAGNETISM; MULTIDRUG RESISTANCE; NEPHROTOXICITY; OXIDATION REDUCTION POTENTIAL; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; STIMULUS RESPONSE; TEMPERATURE; TOXICITY TESTING; ULTRASOUND;

DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; POLYMERS; TEMPERATURE;

EID: 70349132689     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.09.44     Document Type: Review

References (83)

1. Moghimi SM, Hunter AC, Murray JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283-318 (2001).
2. Roco MC: Nanotechnology: convergence with modern biology and medicine. Curr. Opin. Biotechnol. 14, 337-346 (2003).
3. Wilkinson JM: Nanotechnology applications in medicine. Med. Device Technol. 14, 29-31 (2003).
4. Green JJ, Shi J, Chiu E et al.: Biodegradable polymeric vectors for gene delivery to human endothelial cells. Bioconjug. Chem. 17, 1162-1169 (2006).
5. Torchilin VP: Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9, E128-E147 (2007).
6. Muthu MS, Singh S: Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation. Nanomedicine 3, 305-319 (2008).
7. Muthu MS, Singh S: Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine 4, 105-118 (2009).
8. Sahoo SK, Labhasetwar V: Nanotech approaches to drug delivery and imaging. Drug Discov. Today 8, 1112-1120 (2003).
9. Jones M, Leroux J: Polymeric micelles - a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 48, 101-111 (1999).
10. Adams ML, Lavasanifar A, Kwon GS: Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 92, 1343-1355 (2003).
11. Gaucher G, Dufresne MH, Sant VP et al.: Block copolymer micelles: preparation, characterization and application in drug delivery. J. Control. Release 109, 169-188 (2005).
12. Mahmud A, Xiong X, Montazeri H et al.: Polymeric micelles for drug targeting. J. Drug Target. 15, 553-584 (2007).
13. La S, Okano T, Kataoka K: Preparation and characterization of the micelles-forming polymeric drug: indomethacin-incorporated poly(ethylene oxide)-poly(β-benzyl L-aspartate) block copolymer micelles. J. Pharm. Sci. 85, 85-90 (1996).
14. Yamamoto Y, Yasugi K, Harada A et al.: Temperature related change in the properties relevant to drug delivery of poly(ethylene glycol) - poly(D,L-lactide) block copolymer micelles in aqueous milieu. J. Control. Release 82, 359-371 (2002).
15. Nishiyama N, Kataoka K: Current state, achievements, and future prospects of polymeric micelles as nanocarrier for drug and gene delivery. Pharmacol. Ther. 112, 630-648 (2006).
16. Uziely B, Jeffers S, Isacson R et al.: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary Phase I studies. J. Clin. Oncol. 13, 1777-1785 (1995).
17. Muggia F, Hamsworth JL, Jeffers S et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and tcxicity modification by liposomal encapsulation. J. Clin. Oncol. 15, 987-993 (1996).
18. Gordon AN, Fleagle JT, Guthrie D et al.: Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin vs. topotecan. J. Clin. Oncol. 19, 3312-3322 (2001).
19. Matsumura Y, Hamaguchi T, Uta T et al.: Phase I clinical trial and pharmacokinetic evaluation of NK911, micelle-encapsulated doxorubicin. Br. J. Cancer 91, 1775-1781 (2004).
20. Peer D, Karp JM, Hong S et al.: Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
21. Ferrari M: Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5, 161-171 (2005).
22. Nishiyama N, Kataoka K: Development of polymeric micelles for the delivery of antitumor agents. Gan To Kagaku Ryoho 36, 357-361 (2009).
23. Uchino H, Matsumura Y, Negishi T et al.: Cisplatin-incorporated polymeric micelle (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br. J. Cancer 19, 678-687 (2005).
24. Mizumura Y, Matsumura Y, Yokoyama M et al.: Incorporation of the anticancer agent KRN55OO into polymeric micelles diminishes the pulmonary toxicity. Jpn J. Cancer Res. 93, 1237-1243 (2002).
25. Negishi T, Koizumi F, Uchino H et al.: NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitizing agent compared with free paclitaxel. Br. J. Cancer 95, 601-606 (2006).
26. Pridgen EM, Langer R, Farokhzad OC: Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine 2, 669-680 (2007).
27. Yoo HS, Park TG: Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control. Release 96, 273-283 (2004).
28. Sawant RM, Hurley JP, Salmaso S et al.: "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 17, 943-949 (2006).
29. Torchilin V: Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. 71, 431-444 (2009).
30. Ganta S, Devalapally H, Shahiwala A, Amiji M: A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release 126, 187-204 (2008).
31. Singh S, Nalwa HS: Nanotechnology and health safety-toxicity and risk assessments of nanostructured materials on human health. J. Nanosci. Nanotechnol. 7, 3048-3070 (2007).
32. Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46, 149-168 (2001).
33. Yamamoto Y, Nagasaki Y, Kato Y et al.: Long-circulating poly (ethylene glycol)-poly (D,L-lactide) block copolymer micelles with modulated surface charge. J. Control. Release 77, 27-38 (2001).
34. Torchilin VP: Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24, 1-16 (2007).
35. Steinhauser I, Spankuch B, Strebhardt K et al.: Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 27, 4975-4983 (2006).
36. Tiefenauer LX, Kuhne G, Andres RY: Antibody - magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. Bioconjug. Chem. 4, 347-352 (1993).
37. Hood JD, Bednarski M, Frausto R et al.: Tumor regression by targeted gene delivery to tire neovasculature. Science 296, 2404-2407 (2002).
38. Pasqualini R, Ruoslahti E: Organ targeting in vivo using phase display peptide libraries. Nature 380, 364-366 (1996).
39. Pasqualini R, Koivunen E, Ruoslahti E: α v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542-546 (1997).
40. Parker N, Turk MJ, Westrick E et al.: Folate receptor expression in carcinomas and normal tissues determined by a quantitative radio ligand binding assay. Anal. Biochem. 338, 284-293 (2005).
41. Sinha R, Kim GJ, Nie S, Shin DM: Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer. Ther. 5, 1909-1917 (2006).
42. Harris-AL, Hochhauser D: Mechanisms of multidrug resistance in cancer treatment. Acta Oncol. 31, 205-213 (1992).
43. Tsuruo T, Naito M, Tomida A et al.: Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 94, 15-21 (2003).
44. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM: Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 34, 592-602 (2008).
45. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependenr transporters. Nat. Rev. 2, 48-58 (2002).
46. Wu J, Lu Y, Lee A et al.: Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 10, 350-357 (2007).
47. van Vlerken LE, Duan Z, Seiden MV, Amiji MM: Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 67, 4843-4850 (2007).
48. Devalapally H, Shenoy D, Little S et al.: Poly(ethylene oxide)-modified poly(β-amino ester) nanoparticles as a pH-sensitive system for tumor-targated delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model. Cancer Chemother. Pharmacol. 59, 477-484 (2007).
49. Venne A, Li S, Mandeville R et al.: Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug resistant cells. Cancer Res. 56, 3626-3629 (1996).
50. Lee ES, Na K, Bae YH: Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 103, 405-418 (2005).
51. Bae Y, Nishiyama N, Fukushima S et al.: Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 16, 122-130 (2005)
52. Bae Y, Fukushima S, Harada A, Kataoka K: Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew. Chem. Int. Ed. 42, 4640-4643 (2003).
53. Bae Y, Nishiyama N, Fukushima S et al.: Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 16, 122-130 (2005).
54. Bae Y, Jang WD, Nishiyama N et al.: Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol. Biosyst. 1, 242-250 (2005).
55. Lee ES, Na K, Bae YH: Super pH-sensitive multifunctional polymeric micelle. Nano Lett. 5, 325-329 (2005).
56. Klaikherd A, Nagamani C, Thayumanavan S: Multi-stimuli sensitive amphiphilic block copolymer assemblies. J. Am. Chem. Soc. 131(13), 4830-4838 (2009).
57. Lee ES, Gao Z, Kim D et al.: Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance. J. Control. Release 129, 228-236 (2008).
58. Liu SQ, Tong YW, Yang YY: Thermally sensitive micelles self assembled from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)- b-poly(D,L-lactide-co-glycolide) for controlled delivery of paclitaxel. Mol. Biosyst. 1, 158-165 (2005).
59. Chung JE, Yokoyama M, Yamato M et al.: Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly (N-isopropylacrylamide) and poly(butylmethacrylate). J. Control. Release 62, 115-127 (1999).
60. De P, Gondi SR, Sumerlin BS: Folate conjugated thermoresponsive block copolymers: high efficient conjugation and solution self-assembly. Biomacromolecules 9, 1064-1070 (2008).
61. Saito G, Swanson JA, Lee KD: Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55, 199-215 (2003).
62. Cavallaro G, Campisi M, Licciardi M et al.: Reversibly stable thiopolyplexes for intracellular delivery of genes. J. Control. Release 115, 322-334 (2006).
63. Tartaj P, del Puerto Morales M, Veintemillas-Verdaguer S et al.: The preparation of magnetic nanoparticle for applications in biomedicine. J. Phys. D Appl. Phys. 36, R182-R197 (2003).
64. Duguet E, Vasseur S, Mornet S et al.: Magnetic nanoparticles and their applications in medicine. Nanomedicine 1, 157-168 (2006).
65. Cinteza LO, Ohulchanskyy TY, Sahoo Y et al.: Diacyllipid micelle-based nanocarrier for magnetically guided delivery of drugs in photodynamic therapy. Mol. Pharm. 3, 415-423 (2006).
66. 4-OA-g-P(OA-co-NIPAAm) magnetomicelles. J. Biomater. Sci. Polym. Ed. 19, 1249-1259 (2008).
67. Talelli M, Rijcken CJF, Lammers T et al.: Superparamagnetic iron oxide nanoparticles encapsulated in biodegradable thermosensitive polymeric micelles: towards a targeted nanomedicine suitable for image guided drug delivery. Langmuir 25, 2060-2067 (2009).
68. Hong G, Yuan R, Liang B et al.: Folate-functionalized polymeric micelle as hepatic carcinoma-targeted, MRI-ultrasensitive delivery system of antitumor drugs. Biomed. Microdevices 10, 693-700 (2008).
69. Marin A, Muniruzzaman M, Rapoport N: Mechanism of the ultrasonic activation of micellar drug delivery. J. Control. Release 75, 69-81 (2001).
70. Husseini GA, Pitt WG: Ultrasonic-activated micellar drug delivery for cancer treatment. J. Pharm. Sci. 98, 795-811 (2009).
71. Gao Z, Fain HD, Rapoport N: Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. Mol. Pharm. 1, 317-330 (2004).
72. Pruitt JD, Pitt WG: Sequestration and ultrasound-induced release of doxorubicin from stabilized Pluronic P105 micelles. Drug Deliv. 9, 253-258, (2002).
73. 4-loaded polymeric micelles for dual targeting of cancer cells. Polymer 49, 3477-3485 (2008).
74. Nasongkla N, Bey E, Ren J et al.: Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett. 6, 2427-2430 (2006).
75. Moghimi SM, Hunter AC, Murray JC: Nanomedicine: current status and future prospects. FASEB J. 19, 311-330 (2005)
76. Lam KH, Schakenraad JM, Esselbrugge H et al.: The effect of phagocytosis of poly(L-lactic acid) fragments on cellular morphology and viability. J. Biomed. Mat. Res. 27, 1569-1577 (1993).
77. Batrakova EV, Li S, Alakhov VY et al.: Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 304, 845-854 (2003).
78. Nishiyama N, Koizumi F, Okazaki S et al.: Differential gene expression profile between PC-14 cells treated with free cisplatin and cisplatin incorporated polymeric micelles. Bioconj. Chem. 14, 449-457 (2003).
79. Kawaguchi T, Honda T, Nishihara M et al.: Histologicil study on side effects and tumor targeting of a block copolymer micelle on rats. J. Control. Release 136, 240-246 (2009).
80. Tran TD, Caruthers SD, Hughes M et al.: Clinical application of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. Int. J. Nanomedicine 2, 515-526 (2007).
81. Warner S: Diagnostic plus therapy = theranostics. Scientist 18, 38-39 (2004).
82. Sumer B, Gao J: Theranostic nanomedicine for cancer. Nanomedicine 3(2), 137-140 (2008).
83. Jain KK: Role of nanobiotechnology in the development of personalized medicine. Nanomedicine 4(3), 249-252 (2009).